The poc hba1c testing market size has grown rapidly in recent years. It will grow from $1.02 billion in 2025 to $1.14 billion in 2026 at a compound annual growth rate (CAGR) of 11.9%. The growth in the historic period can be attributed to rising prevalence of diabetes globally, increased clinical reliance on long-term glucose monitoring, expansion of outpatient diagnostic services, growing awareness of early diabetes diagnosis, availability of compact diagnostic instruments.
The poc hba1c testing market size is expected to see rapid growth in the next few years. It will grow to $1.76 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to increasing adoption of decentralized diagnostics, rising demand for home care testing solutions, expansion of digital diabetes management programs, growing focus on preventive healthcare, increasing investments in rapid diagnostic technologies. Major trends in the forecast period include increasing adoption of rapid point-of-care hba1c devices, growing use of portable and handheld testing systems, rising demand for home-based diabetes monitoring, expansion of integrated poc diagnostic platforms, enhanced focus on test accuracy and standardization.
The rising global burden of diabetes is fueling growth in point-of-care (POC) HbA1c testing. Diabetes is a chronic metabolic condition marked by persistently high blood glucose levels, requiring regular monitoring to reduce the risk of complications such as neuropathy, cardiovascular disorders, and kidney damage. The growing incidence of diabetes is largely attributed to sedentary lifestyles, poor dietary habits, increasing obesity rates, and aging populations worldwide. As a result, demand is increasing for rapid, convenient, and reliable glycemic assessment across clinics, pharmacies, and home-care environments, where POC HbA1c testing enables timely clinical decisions. For example, in 2025, according to the International Diabetes Federation, approximately 589 million adults aged 20-79 were living with diabetes in 2024, with projections indicating this figure could rise to 853 million by 2050, and more than four out of five affected adults residing in low- and middle-income countries. This expanding patient base is therefore supporting continued growth in POC HbA1c testing.
Companies operating in the point-of-care HbA1c testing space are increasingly incorporating embedded internal verification systems to improve accuracy, minimize errors, and strengthen confidence in near-patient diagnostics. These automated self-check features continuously assess environmental conditions, sample quality, and assay performance during each test, helping to prevent inaccurate results. For instance, in July 2024, Siemens Healthineers launched its next-generation Atellica DCA Analyzer for point-of-care use. The system integrates proprietary Auto-Checks Technology that performs continuous internal calibrations throughout the testing process, including checks for environmental stability, airflow and temperature control, sample volume and integrity, optical clarity, and analytical precision. This automated monitoring enables delivery of lab-comparable HbA1c results within 4-5 minutes while reducing dependence on operator oversight. Such capabilities help lower pre-analytical error rates, enhance result reliability, and facilitate wider adoption of point-of-care testing in resource-limited settings.
In February 2024, HemoCue AB, a Sweden-based provider of POC HbA1c testing solutions including the HemoCue HbA1c 501 System, entered into a strategic partnership with Novo Nordisk to expand diabetes diagnosis and monitoring for children in low- and middle-income countries. Under this collaboration, HemoCue supports Novo Nordisk’s Changing Diabetes in Children programme, which delivered free, life-saving diabetes treatment to more than 52,000 children in the previous year and has set a target of reaching 100,000 children by 2030. The partnership underscores a shared commitment to improving access to early diagnosis and ongoing glycemic monitoring for pediatric patients with type 1 diabetes in underserved regions.
Major companies operating in the poc hba1c testing market are F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Bio-Rad Laboratories Inc, Menarini Group, Danaher Corporation, Tosoh Bioscience Inc, ARKRAY Inc, i-SENS Inc, Abbott Laboratories, Trinity Biotech plc, Aina Blood Monitoring System, Getein Biotech Inc, Sugentech Inc, Alere Inc, EKF Diagnostics, HemoCue, PTS Diagnostics, Osang Healthcare, Ortho Clinical Diagnostics, Ascensia, Platinum Equity (LifeScan), Becton Dickinson and Company, Kainico Ltd, Evia Medical Technologies, Agamatrix Inc, Bionime Corporation.
North America was the largest region in the POC HbA1C testing market in 2025. Africa is expected to be the fastest-growing region in the forecast- period. The regions covered in the poc hba1c testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the poc hba1c testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the poc hba1c testing market by increasing costs of imported reagents, biosensors, electronic components, and diagnostic consumables used in instruments and test kits. Hospitals and outpatient care providers in North America and Europe are most affected due to reliance on imported diagnostic devices, while Asia-Pacific faces pricing pressure on device manufacturing. These tariffs are raising device procurement costs and slowing replacement cycles. However, they are also encouraging localized manufacturing, regional reagent production, and innovation in cost-efficient point-of-care testing solutions.
The poc hba1c testing market research report is one of a series of new reports that provides poc hba1c testing market statistics, including poc hba1c testing industry global market size, regional shares, competitors with a poc hba1c testing market share, detailed poc hba1c testing market segments, market trends and opportunities, and any further data you may need to thrive in the poc hba1c testing industry. This poc hba1c testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
POC HbA1C testing devices are designed for diagnosing average levels of glucose in patients' blood and managing both type I and type II diabetes mellitus. Diabetes is a chronic disease that occurs when either an inadequate amount of insulin is produced by the pancreas or when the body cannot use the insulin it produces effectively. POC HbA1C testing assesses the average level of blood sugar over 2 to 3 months in an individual.
The main products of POC HbA1C testing include instruments and consumables. Instruments refer to measuring devices for determining the present value of a quantity under observation. The technologies involved in POC HbA1C testing include ion-exchange HPLC, enzymatic assay, affinity binding chromatography, turbidimetric inhibition immunoassay, and others. Various end-users utilize these testing devices, including hospitals, physician offices or outpatient centers, home care providers, and other end-users.
The POC HbA1C testing market consists of sales of small instruments, portable instruments, and HbA1C testing devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The poc hba1c testing market size is expected to see rapid growth in the next few years. It will grow to $1.76 billion in 2030 at a compound annual growth rate (CAGR) of 11.4%. The growth in the forecast period can be attributed to increasing adoption of decentralized diagnostics, rising demand for home care testing solutions, expansion of digital diabetes management programs, growing focus on preventive healthcare, increasing investments in rapid diagnostic technologies. Major trends in the forecast period include increasing adoption of rapid point-of-care hba1c devices, growing use of portable and handheld testing systems, rising demand for home-based diabetes monitoring, expansion of integrated poc diagnostic platforms, enhanced focus on test accuracy and standardization.
The rising global burden of diabetes is fueling growth in point-of-care (POC) HbA1c testing. Diabetes is a chronic metabolic condition marked by persistently high blood glucose levels, requiring regular monitoring to reduce the risk of complications such as neuropathy, cardiovascular disorders, and kidney damage. The growing incidence of diabetes is largely attributed to sedentary lifestyles, poor dietary habits, increasing obesity rates, and aging populations worldwide. As a result, demand is increasing for rapid, convenient, and reliable glycemic assessment across clinics, pharmacies, and home-care environments, where POC HbA1c testing enables timely clinical decisions. For example, in 2025, according to the International Diabetes Federation, approximately 589 million adults aged 20-79 were living with diabetes in 2024, with projections indicating this figure could rise to 853 million by 2050, and more than four out of five affected adults residing in low- and middle-income countries. This expanding patient base is therefore supporting continued growth in POC HbA1c testing.
Companies operating in the point-of-care HbA1c testing space are increasingly incorporating embedded internal verification systems to improve accuracy, minimize errors, and strengthen confidence in near-patient diagnostics. These automated self-check features continuously assess environmental conditions, sample quality, and assay performance during each test, helping to prevent inaccurate results. For instance, in July 2024, Siemens Healthineers launched its next-generation Atellica DCA Analyzer for point-of-care use. The system integrates proprietary Auto-Checks Technology that performs continuous internal calibrations throughout the testing process, including checks for environmental stability, airflow and temperature control, sample volume and integrity, optical clarity, and analytical precision. This automated monitoring enables delivery of lab-comparable HbA1c results within 4-5 minutes while reducing dependence on operator oversight. Such capabilities help lower pre-analytical error rates, enhance result reliability, and facilitate wider adoption of point-of-care testing in resource-limited settings.
In February 2024, HemoCue AB, a Sweden-based provider of POC HbA1c testing solutions including the HemoCue HbA1c 501 System, entered into a strategic partnership with Novo Nordisk to expand diabetes diagnosis and monitoring for children in low- and middle-income countries. Under this collaboration, HemoCue supports Novo Nordisk’s Changing Diabetes in Children programme, which delivered free, life-saving diabetes treatment to more than 52,000 children in the previous year and has set a target of reaching 100,000 children by 2030. The partnership underscores a shared commitment to improving access to early diagnosis and ongoing glycemic monitoring for pediatric patients with type 1 diabetes in underserved regions.
Major companies operating in the poc hba1c testing market are F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Bio-Rad Laboratories Inc, Menarini Group, Danaher Corporation, Tosoh Bioscience Inc, ARKRAY Inc, i-SENS Inc, Abbott Laboratories, Trinity Biotech plc, Aina Blood Monitoring System, Getein Biotech Inc, Sugentech Inc, Alere Inc, EKF Diagnostics, HemoCue, PTS Diagnostics, Osang Healthcare, Ortho Clinical Diagnostics, Ascensia, Platinum Equity (LifeScan), Becton Dickinson and Company, Kainico Ltd, Evia Medical Technologies, Agamatrix Inc, Bionime Corporation.
North America was the largest region in the POC HbA1C testing market in 2025. Africa is expected to be the fastest-growing region in the forecast- period. The regions covered in the poc hba1c testing market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the poc hba1c testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the poc hba1c testing market by increasing costs of imported reagents, biosensors, electronic components, and diagnostic consumables used in instruments and test kits. Hospitals and outpatient care providers in North America and Europe are most affected due to reliance on imported diagnostic devices, while Asia-Pacific faces pricing pressure on device manufacturing. These tariffs are raising device procurement costs and slowing replacement cycles. However, they are also encouraging localized manufacturing, regional reagent production, and innovation in cost-efficient point-of-care testing solutions.
The poc hba1c testing market research report is one of a series of new reports that provides poc hba1c testing market statistics, including poc hba1c testing industry global market size, regional shares, competitors with a poc hba1c testing market share, detailed poc hba1c testing market segments, market trends and opportunities, and any further data you may need to thrive in the poc hba1c testing industry. This poc hba1c testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
POC HbA1C testing devices are designed for diagnosing average levels of glucose in patients' blood and managing both type I and type II diabetes mellitus. Diabetes is a chronic disease that occurs when either an inadequate amount of insulin is produced by the pancreas or when the body cannot use the insulin it produces effectively. POC HbA1C testing assesses the average level of blood sugar over 2 to 3 months in an individual.
The main products of POC HbA1C testing include instruments and consumables. Instruments refer to measuring devices for determining the present value of a quantity under observation. The technologies involved in POC HbA1C testing include ion-exchange HPLC, enzymatic assay, affinity binding chromatography, turbidimetric inhibition immunoassay, and others. Various end-users utilize these testing devices, including hospitals, physician offices or outpatient centers, home care providers, and other end-users.
The POC HbA1C testing market consists of sales of small instruments, portable instruments, and HbA1C testing devices. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Poc Hba1C Testing Market Characteristics
3. Poc Hba1C Testing Market Supply Chain Analysis
4. Global Poc Hba1C Testing Market Trends and Strategies
5. Poc Hba1C Testing Market Analysis of End Use Industries
7. Global Poc Hba1C Testing Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Poc Hba1C Testing Total Addressable Market (TAM) Analysis for the Market
9. Poc Hba1C Testing Market Segmentation
10. Poc Hba1C Testing Market Regional and Country Analysis
11. Asia-Pacific Poc Hba1C Testing Market
12. China Poc Hba1C Testing Market
13. India Poc Hba1C Testing Market
14. Japan Poc Hba1C Testing Market
15. Australia Poc Hba1C Testing Market
16. Indonesia Poc Hba1C Testing Market
17. South Korea Poc Hba1C Testing Market
18. Taiwan Poc Hba1C Testing Market
19. South East Asia Poc Hba1C Testing Market
20. Western Europe Poc Hba1C Testing Market
21. UK Poc Hba1C Testing Market
22. Germany Poc Hba1C Testing Market
23. France Poc Hba1C Testing Market
24. Italy Poc Hba1C Testing Market
25. Spain Poc Hba1C Testing Market
26. Eastern Europe Poc Hba1C Testing Market
27. Russia Poc Hba1C Testing Market
28. North America Poc Hba1C Testing Market
29. USA Poc Hba1C Testing Market
30. Canada Poc Hba1C Testing Market
31. South America Poc Hba1C Testing Market
32. Brazil Poc Hba1C Testing Market
33. Middle East Poc Hba1C Testing Market
34. Africa Poc Hba1C Testing Market
36. Poc Hba1C Testing Market Competitive Landscape and Company Profiles
37. Poc Hba1C Testing Market Other Major and Innovative Companies
40. Poc Hba1C Testing Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
Poc Hba1C Testing Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses poc hba1c testing market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for poc hba1c testing? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The poc hba1c testing market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type of Product: Instruments; Consumables2) By Technology: Ion-Exchange HPLC; Enzymatic Assay; Affinity Binding Chromatography; Immunoassay; Other Technologies
3) By End User: Hospitals; Physician Office Or Outpatient Center; Home Care; Other End Users
Subsegments:
1) By Instruments: Handheld HbA1c Testing Devices; Portable HbA1c Analyzers; Desktop HbA1c Testing Systems; Integrated Point Of Care Testing Systems2) By Consumables: Test Strips; Control Solutions; Reagents; Calibration Solutions; Sample Collection Devices
Companies Mentioned: F. Hoffmann-La Roche Ltd; Siemens Healthineers AG; Bio-Rad Laboratories Inc; Menarini Group; Danaher Corporation; Tosoh Bioscience Inc; ARKRAY Inc; i-SENS Inc; Abbott Laboratories; Trinity Biotech plc; Aina Blood Monitoring System; Getein Biotech Inc; Sugentech Inc; Alere Inc; EKF Diagnostics; HemoCue; PTS Diagnostics; Osang Healthcare; Ortho Clinical Diagnostics; Ascensia; Platinum Equity (LifeScan); Becton Dickinson and Company; Kainico Ltd; Evia Medical Technologies; Agamatrix Inc; Bionime Corporation
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Poc Hba1C Testing market report include:- F. Hoffmann-La Roche Ltd
- Siemens Healthineers AG
- Bio-Rad Laboratories Inc
- Menarini Group
- Danaher Corporation
- Tosoh Bioscience Inc
- ARKRAY Inc
- i-SENS Inc
- Abbott Laboratories
- Trinity Biotech plc
- Aina Blood Monitoring System
- Getein Biotech Inc
- Sugentech Inc
- Alere Inc
- EKF Diagnostics
- HemoCue
- PTS Diagnostics
- Osang Healthcare
- Ortho Clinical Diagnostics
- Ascensia
- Platinum Equity (LifeScan)
- Becton Dickinson and Company
- Kainico Ltd
- Evia Medical Technologies
- Agamatrix Inc
- Bionime Corporation
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 1.14 Billion |
| Forecasted Market Value ( USD | $ 1.76 Billion |
| Compound Annual Growth Rate | 11.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 27 |
